RT Journal Article
SR Electronic
T1 City-wide school-located influenza vaccination: a retrospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.03.21256546
DO 10.1101/2021.05.03.21256546
A1 Jade Benjamin-Chung
A1 Benjamin F. Arnold
A1 Kunal Mishra
A1 Chris J. Kennedy
A1 Anna Nguyen
A1 Nolan N. Pokpongkiat
A1 Stephanie Djajadi
A1 Anmol Seth
A1 Nicola P. Klein
A1 Alan E. Hubbard
A1 Arthur Reingold
A1 John M. Colford, Jr.
YR 2021
UL http://medrxiv.org/content/early/2021/05/04/2021.05.03.21256546.abstract
AB Background We measured the effectiveness of a city-wide school-located influenza vaccination (SLIV) program implemented in over 102 elementary schools in Oakland, California.Methods We conducted a retrospective cohort study among Kaiser Permanente Northern California (KPNC) members of all ages residing in either the intervention or a multivariate-matched comparison site from September 2011 - August 2017. Outcomes included medically attended acute respiratory illness (MAARI), influenza hospitalization, and Oseltamivir prescriptions. We estimated difference-in-differences (DIDs) in 2014-15, 2015-16, and 2016-17 using generalized linear models and adjusted for race, ethnicity, age, sex, health plan, and language.Results Pre-intervention member characteristics were similar between sites. Among school-aged children, SLIV was associated with lower Oseltamivir prescriptions per 1,000 (DIDs: −3.5 (95% CI −5.5, −1.5) in 2015-16; −4.0 (95% CI −6.5, −1.6) in 2016-17) but not with other outcomes. SLIV was associated with lower MAARI per 1,000 in adults 65+ years (2014-15: −13.2, 95% CI −23.2, −3.2; 2015-16: −21.5, 95% CI −31.1, −11.9; 2016-17: −13.0, 95% CI −23.2, −2.9). There were few significant associations with other outcomes among adults.Conclusions A city-wide SLIV intervention was associated with lower Oseltamivir prescriptions in school-aged children and lower MAARI among people over 65 years, suggesting possible indirect effects of SLIV among older adults.Competing Interest StatementNPK reports research support from Protein Science (Sanofi Pasteur) and Sanofi Pasteur for unrelated influenza vaccine studies and from GlaxoSmithKline, Merck & Co, and Pfizer for unrelated studies. JBC, BFA, KM, CJK, AN, NNP, SD, AS, AEH, AR, JMC report no conflicts.Funding StatementThis work was supported by a grant from the Flu Lab (https://theflulab.org/) to the University of California, Berkeley (Grant number: 20142281; PI: AR).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Committee for the Protection of Human Subjects at the University of California, Berkeley (Protocol # 2017-03-9741) and the KPNC Institutional Review Board (Protocol #CN-16-2825).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data from this study is not available due to human subjects protections.